NCT03520075: Study of ASTX029 in Subjects With Advanced Solid Tumors

NCT03520075
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: MAPK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with documented gene alterations in the MAPK pathway will be eligible for phase 2 of the study
Exclusions: Patients with known untreated unstable brain metastases- see trial for details; Patients with prior treatment with ERK inhibitors
https://ClinicalTrials.gov/show/NCT03520075

Comments are closed.

Up ↑